Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.

Ganapathi MK, Jones WD, Sehouli J, Michener CM, Braicu IE, Norris EJ, Biscotti CV, Vaziri SA, Ganapathi RN.

Int J Cancer. 2016 Feb 1;138(3):679-88. doi: 10.1002/ijc.29815. Epub 2015 Sep 10.

2.

Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.

Vaziri SA, Tavares EJ, Golshayan AR, Rini BI, Aydin H, Zhou M, Sercia L, Wood L, Ganapathi MK, Bukowski RM, Ganapathi R.

Front Oncol. 2012 May 28;2:51. doi: 10.3389/fonc.2012.00051. eCollection 2012.

3.

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi R.

Cancer. 2012 Apr 1;118(7):1946-54. doi: 10.1002/cncr.26491. Epub 2011 Aug 31.

4.

CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.

Fader AN, Rasool N, Vaziri SA, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, Rojas-Espaillat L, Belinson JL, Ganapathi MK, Ganapathi R.

Anticancer Res. 2010 Dec;30(12):4791-8.

PMID:
21187454
5.

Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors.

Vaziri SA, Kim J, Ganapathi MK, Ganapathi R.

Curr Oncol Rep. 2010 Mar;12(2):102-8. doi: 10.1007/s11912-010-0085-4. Review.

PMID:
20425594
6.

Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.

Vaziri SA, Grabowski DR, Hill J, Rybicki LR, Burk R, Bukowski RM, Ganapathi MK, Ganapathi R.

Anticancer Res. 2009 Aug;29(8):2961-9.

7.

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.

PMID:
18635227
8.

Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.

Chikamori K, Hill JE, Grabowski DR, Zarkhin E, Grozav AG, Vaziri SA, Wang J, Gudkov AV, Rybicki LR, Bukowski RM, Yen A, Tanimoto M, Ganapathi MK, Ganapathi R.

Leukemia. 2006 Oct;20(10):1809-18. Epub 2006 Aug 17.

PMID:
16932348
9.

Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.

Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T.

Anticancer Res. 2006 May-Jun;26(3A):1869-76.

10.

Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.

Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK, Ganapathi R.

Mol Cancer Ther. 2005 Dec;4(12):1880-90.

11.

c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.

Vaziri SA, Grabowski DR, Tabata M, Holmes KA, Sterk J, Takigawa N, Bukowski RM, Ganapathi MK, Ganapathi R.

Anticancer Res. 2003 Sep-Oct;23(5A):3657-61.

PMID:
14666661
12.

Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers.

Archey WB, McEachern KA, Robson M, Offit K, Vaziri SA, Casey G, Borg A, Arrick BA.

Oncogene. 2002 Oct 10;21(46):7034-41.

13.

Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.

Ganapathi R, Vaziri SA, Tabata M, Takigawa N, Grabowski DR, Bukowski RM, Ganapathi MK.

Curr Pharm Des. 2002;8(22):1945-58. Review.

PMID:
12171521
14.

Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.

Vaziri SA, Tubbs RR, Darlington G, Casey G.

Mol Pathol. 2001 Aug;54(4):259-63.

15.

Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.

Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G.

Clin Cancer Res. 2001 Jul;7(7):1937-45.

16.

Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects.

Vaziri SA, Hughes NC, Sampson H, Darlington G, Jewett MA, Grant DM.

Pharmacogenetics. 2001 Feb;11(1):7-20.

PMID:
11207033
17.

Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.

Vaziri SA, Krumroy LM, Rostai M, Casey G.

Hum Mutat. 2001;17(1):74.

PMID:
11139249

Supplemental Content

Loading ...
Support Center